Evofem Biosciences Appoints Russell Barrans as Chief Commercial Officer

SAN DIEGO, CA — Evofem Biosciences announces that Russell Barrans has been named Chief Commercial Officer effective immediately. In this role, Mr. Barrans will have responsibility for all global commercial activities including: marketing, sales, public relationships, analytics, KOL engagement, and life cycle management of the Evofem Biosciences product portfolio. He will report directly to Saundra Pelletier, CEO.

“We are excited to have Russell join the Evofem executive team in this important role.  His deep experience in the women’s healthcare industry and his US and global launch experience will allow him to have immediate impact on the business,” said Pelletier.  Prior to joining the Evofem executve team, Mr. Barrans was the Sr. Vice-President for Marketing and Sales for the organization.

In his previous role Mr. Barrans was part of the TEVA Pharmaceuticals leadership team as the Director of Women’s Healthcare Marketing .  He also held senior level positions at global and domestic companies including Bayer and led his own strategic consulting firm servicing biotech and pharmaceutical brands. Mr. Barrans has worked in many aspects of the women’s healthcare pharmaceutical industry and has overseen the launch of numerous innovative contraceptive brands including Mirena®, and Plan B One-Step® OTC.

Mr. Barrans graduated from California Coast University with a Bachelor’s of Science in Business Administration and holds an MBA from California Coast University.


 About Evofem Biosciences 

Evofem Biosciences develops and commercializes innovative products that support and promote women as the primary healthcare consumer. Evofem Biosciences is currently identifying and developing new and novel products that specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products that address or promote general health and wellbeing.  Evofem Biosciences’lead product candidateis: Amphora®, a vaginal contraceptive gel, which is currently in Phase III clinical studies. For more information on the Company, visit www.evofem.com

Evofem Biosciences Media Contact

Russ Barrans
(267) 907-4752